2016 European Guidelines on cardiovascular disease prevention in clinical practice

The guideline authors did not run a new experiment. Instead, they systematically reviewed the existing evidence to answer: *What interventions, at what doses or targets, most effectively prevent first or recurrent cardiovascular events (heart attacks, strokes, cardiovascular death) in people with and without existing disease?*

The "interventions" tested across the underlying studies include:

**Blood pressure targets:** Lowering systolic blood pressure to <140 mmHg (general population) or <130 mmHg (higher-risk groups, e.g., those with diabetes or chronic kidney disease).

**LDL cholesterol targets:** Lowering LDL cholesterol to <1.8 mmol/L (~70 mg/dL) for very high-risk individuals, <2.6 mmol/L (~100 mg/dL) for high-risk, and <3.0 mmol/L (~115 mg/dL) for moderate-risk.

**Physical activity:** At least 150 minutes per week of moderate-intensity aerobic activity, or 75 minutes of vigorous activity, plus resistance training twice weekly.

**Dietary patterns:** Mediterranean diet (high in olive oil, nuts, fish, legumes, vegetables, low in red meat and processed foods).

**Smoking cessation:** Any intervention that helps people stop smoking (counselling, nicotine replacement, medications).

**Glycaemic control:** HbA1c <7.0% (53 mmol/mol) for most people with diabetes, with individualisation.

**Antiplatelet therapy:** Low-dose aspirin (75–100 mg/day) for secondary prevention (people with existing cardiovascular disease) but not routinely for primary prevention.

The comparator in most underlying studies was either no intervention, placebo, or standard care (less aggressive targets).

Outcome measures were:

**Primary:** Major adverse cardiovascular events (MACE) — a composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death.

**Secondary:** All-cause mortality, revascularisation procedures (stents, bypass surgery), hospitalisation for heart failure, and quality of life.

The guideline synthesises data from hundreds of studies involving hundreds of thousands of participants. The populations covered include:

**Primary prevention:** Adults aged 40–75 without known cardiovascular disease, with varying risk levels (low, moderate, high, very high based on SCORE risk charts).

**Secondary prevention:** Adults of any age with established cardiovascular disease (prior heart attack, stroke, peripheral artery disease, or revascularisation).

**Specific subgroups:** People with diabetes, chronic kidney disease, familial hypercholesterolaemia, and older adults (>65).

**Exclusions from most underlying trials:** Pregnant women, people with terminal illness, those with severe frailty, and people with contraindications to specific medications.

The guideline explicitly notes that most trial evidence comes from white European populations, with limited data from South Asian, Black, and other ethnic groups — a significant limitation.

The guideline does not use a single instrument. Instead, it aggregates findings from studies using standardised clinical measurements:

**Blood pressure:** Office-based auscultatory or oscillometric sphygmomanometry (systolic and diastolic, mmHg). Some studies used 24-hour ambulatory blood pressure monitoring.

**Cholesterol:** Fasting venous blood samples measured for total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides (mmol/L or mg/dL).

**Blood sugar:** Fasting plasma glucose (mmol/L) and HbA1c (percentage or mmol/mol) for diabetes diagnosis and control.

**Physical activity:** Self-reported questionnaires (e.g., International Physical Activity Questionnaire, IPAQ) or accelerometry in some studies.

**Diet:** Food frequency questionnaires, 24-hour dietary recalls, or adherence scores (e.g., Mediterranean Diet Adherence Screener, 0–14 scale).

**Smoking status:** Self-reported (current, former, never smoker) sometimes biochemically verified with cotinine levels.

**Cardiovascular risk:** SCORE risk charts (Systematic COronary Risk Evaluation) — a 10-year risk of fatal cardiovascular disease based on age, sex, smoking, systolic blood pressure, and total cholesterol. SCORE ranges from <1% (low) to ≥10% (very high).

**Study design:** This is a clinical practice guideline, not a single experiment. The authors followed a structured process:

1. **Systematic literature search:** They searched PubMed, Embase, and Cochrane databases for randomised controlled trials, meta-analyses, and large observational studies published between 2010 and 2015, plus landmark older trials.

2. **Evidence grading:** Each recommendation was assigned a class (I = recommended, IIa = should be considered, IIb = may be considered, III = not recommended) and a level of evidence (A = multiple RCTs or meta-analyses, B = single RCT or large observational studies, C = expert opinion or small studies).

3. **Consensus process:** A panel of 15 experts from the European Society of Cardiology and other European societies drafted recommendations, which were then reviewed by external experts and revised.

4. **Risk stratification:** The guideline uses the SCORE system to categorise individuals into low, moderate, high, and very high risk, and tailors recommendations accordingly.

**What this design can prove:**

The guideline provides the best available synthesis of high-quality evidence. When a recommendation is Class I, Level A (e.g., statins for secondary prevention), it means multiple large RCTs have shown a clear benefit with consistent results.

The SCORE risk system is validated in European populations and allows personalised risk estimation.

**What this design cannot prove:**

A guideline is not a single experiment. It cannot establish causality for any specific intervention in an individual — it only summarises population-level averages.

Recommendations may not apply to people not represented in the underlying trials (e.g., ethnic minorities, very elderly, people with multiple comorbidities).

The guideline is based on evidence available up to 2015. Some recommendations may be outdated (e.g., more recent trials have questioned aggressive blood pressure targets in some groups).

The guideline cannot account for individual variability in response to interventions (e.g., some people get minimal LDL reduction from statins, others get muscle pain).

**Major methodological weaknesses:**

**No formal meta-analysis:** The authors did not perform a quantitative synthesis of all studies. Recommendations are based on narrative review and expert consensus, which can introduce bias.

**Industry funding:** Many of the underlying trials were funded by pharmaceutical companies. The guideline authors declared conflicts of interest, but the evidence base itself is influenced by industry-sponsored research.

**Limited inclusion of newer evidence:** The cut-off at 2015 means that trials published after (e.g., SPRINT on intensive blood pressure lowering, REDUCE-IT on omega-3 fatty acids) are not incorporated.

**Population homogeneity:** The SCORE system was developed from European cohorts. It may over- or under-estimate risk in non-European populations.

The guideline's key findings are presented as recommendations with supporting evidence. Below are the most actionable ones with their evidence grades:

**Blood pressure targets:**

For people with very high cardiovascular risk (established CVD, diabetes with target organ damage, severe CKD): target systolic BP <130 mmHg (Class I, Level A — based on multiple RCTs including ADVANCE, ACCORD, and meta-analyses).

For people with moderate-to-high risk: target systolic BP <140 mmHg (Class I, Level A).

For people with low risk: target systolic BP <140 mmHg (Class I, Level C — expert opinion, no large RCTs in this group).

Diastolic BP target: <90 mmHg for all (Class I, Level A).

**LDL cholesterol targets:**

Very high risk: LDL <1.8 mmol/L (~70 mg/dL) or at least 50% reduction from baseline (Class I, Level A — based on statin trials like 4S, CARE, LIPID, TNT, and meta-analyses by the Cholesterol Treatment Trialists' Collaboration).

High risk: LDL <2.6 mmol/L (~100 mg/dL) (Class I, Level A).

Moderate risk: LDL <3.0 mmol/L (~115 mg/dL) (Class I, Level C).

For every 1 mmol/L reduction in LDL, risk of major vascular events falls by about 22% (from meta-analysis of 26 statin trials, n=170,000).

**Physical activity:**

At least 150 minutes/week of moderate-intensity aerobic activity (e.g., brisk walking, cycling) OR 75 minutes/week of vigorous activity (e.g., running, swimming) (Class I, Level A — based on large observational cohorts and some RCTs).

Resistance training at least 2 days/week (Class I, Level B).

Sedentary time should be minimised (Class I, Level B — observational data showing increased risk with prolonged sitting independent of exercise).

**Diet:**

Mediterranean diet supplemented with extra-virgin olive oil (30–50 g/day) or nuts (30 g/day) reduces major cardiovascular events by about 30% over 5 years (Class I, Level A — based on the PREDIMED trial, n=7,447).

Saturated fat should be <10% of total energy intake (Class I, Level A — from ecological and cohort studies).

Dietary fibre intake should be 30–45 g/day (Class I, Level B).

Salt intake <5 g/day (Class I, Level A — from DASH-Sodium and other trials).

**Smoking cessation:**

All smokers should be advised to quit (Class I, Level A).

Nicotine replacement therapy, bupropion, or varenicline should be offered (Class I, Level A).

Smoking cessation reduces cardiovascular mortality by about 36% over 5 years (from observational studies).

**Glycaemic control in diabetes:**

HbA1c target <7.0% (53 mmol/mol) for most adults with diabetes (Class I, Level A — from UKPDS and ADVANCE trials).

Less stringent targets (HbA1c <8.0%) for those with long-standing diabetes, advanced complications, or frailty (Class I, Level C).

**Antiplatelet therapy:**

Low-dose aspirin (75–100 mg/day) is recommended for secondary prevention (Class I, Level A — from meta-analysis of 6 trials showing ~25% reduction in serious vascular events).

Aspirin is not recommended for primary prevention in people without CVD (Class III, Level A — from recent trials showing no net benefit due to bleeding risk).

Translated into plain English:

**LDL reduction:** If you lower your LDL by 1 mmol/L (about 38 mg/dL) with a statin, your risk of a heart attack or stroke drops by roughly one-fifth. For someone with a 20% 10-year risk, that's a reduction to about 16% — meaning 4 out of 100 people would avoid an event.

**Blood pressure lowering:** Reducing systolic BP by 10 mmHg reduces cardiovascular risk by about 20% (from meta-analysis of 147 trials). For someone with a 20% 10-year risk, that drops to about 16%.

**Mediterranean diet:** In the PREDIMED trial, the Mediterranean diet with extra olive oil or nuts reduced major cardiovascular events by about 30% over 5 years. That means if 100 high-risk people followed a low-fat diet, about 10 would have an event; if they followed the Mediterranean diet, about 7 would.

**Physical activity:** Meeting the 150-minute/week target is associated with about a 20–30% lower risk of cardiovascular disease compared to being sedentary (from large cohort studies). The effect is dose-dependent: more activity gives more benefit, but even small increases help.

**Smoking cessation:** Quitting smoking reduces cardiovascular mortality by about 36% over 5 years. For a 50-year-old smoker with a 20% 10-year risk, quitting brings that down to about 13%.

**What the authors acknowledge:**

The guideline is based on evidence available up to 2015; newer trials may change recommendations.

The SCORE risk system may not be accurate for all European populations (e.g., Southern vs. Northern Europe have different baseline risks).

Many recommendations are based on trials that excluded older adults (>75), women, and ethnic minorities.

Adherence to lifestyle recommendations is poor in real-world settings; the guideline does not address how to improve adherence.

**What a critical reader would note:**

**Industry influence:** Many of the authors had financial ties to pharmaceutical companies (statins, antihypertensives, antidiabetic drugs). While conflicts were declared, the evidence base itself is heavily industry-funded.

**Lack of individualisation:** The guideline gives population-level targets, but individual responses vary widely. For example, some people get minimal LDL reduction from statins due to genetic variants; others get significant muscle pain.

**Over-reliance on surrogate endpoints:** LDL and blood pressure are surrogate markers, not direct measures of cardiovascular events. While the link is strong, some interventions that lower LDL (e.g., certain drugs) have not shown event reduction.

**Dietary recommendations are based on limited RCTs:** The PREDIMED trial is the only large RCT of the Mediterranean diet; it was stopped early and had randomisation issues (some participants were not properly randomised). Other dietary recommendations rely on observational data, which cannot prove causation.

**Physical activity evidence is mostly observational:** The 150-minute recommendation comes from cohort studies, not RCTs. People who exercise more also tend to have healthier diets, smoke less, and have higher socioeconomic status — confounders that are hard to fully adjust for.

**No consideration of time-restricted eating or intermittent fasting:** These were not studied in the evidence base reviewed.

**The guideline does not address polygenic risk scores or personalised medicine:** It treats everyone with the same risk factors identically, ignoring genetic differences that affect drug metabolism and disease risk.

For someone running their own n=1 experiment:

### What to test

Choose one intervention at a time. Do not try to change everything at once — you won't know what worked.

**Option A: Blood pressure lowering**

Test: Reducing sodium intake to <5 g/day (about 1 teaspoon of salt) OR increasing aerobic exercise to 150 min/week.

Duration: 4–8 weeks to see a measurable change in blood pressure.

Measure: Home blood pressure monitor (validated device, e.g., Omron). Take readings at the same time each morning (after voiding, before breakfast, seated, feet flat, arm at heart level). Record 3 readings per session, average them.

Confounds: Stress, caffeine (avoid 30 min before), alcohol, time of day, room temperature, talking during measurement.

Positive result: Systolic BP drops by 5–10 mmHg from baseline.

**Option B: LDL cholesterol reduction**

Test: Replace saturated fats (butter, red meat, full-fat dairy, coconut oil) with unsaturated fats (olive oil, avocado, nuts, fatty fish) OR add 2–3 g/day of plant sterols/stanols (found in fortified spreads or supplements).

Duration: 4–12 weeks (LDL changes can be seen in 4 weeks, but 12 weeks is more reliable).

Measure: Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) from a blood draw. Do not use home finger-prick tests — they are less accurate for LDL.

Confounds: Weight changes (losing weight lowers LDL), alcohol intake (raises HDL but can raise triglycerides), recent illness (can temporarily lower LDL), time of day (fasting required, 9–12 hours).

Positive result: LDL drops by 0.5–1.0 mmol/L (about 20–40 mg/dL).

**Option C: Mediterranean diet adherence**

Test: Follow a Mediterranean diet (daily: 30 g nuts, 30–50 g extra-virgin olive oil, 2+ servings vegetables, 2+ servings fruit, 2+ servings fish/week, legumes 2+/week; limit red meat to <2 servings/week, avoid